Steffen is cell biologist with a strong expertise in early stage development of therapeutic antibodies. Steffen holds a degree from the University of Heidelberg in biology and did his PhD in the Tumor Immunology Programme of the German Cancer Research Center (DKFZ) in Heidelberg. He then joined the German antibody pioneer MorphoSys in Martinsried near Munich to work on the identification and characterization of therapeutic antibody candidates using MorphoSys’ phage display libraries. He participated in customer-initiated projects, e.g. for Novartis and Daiichi-Sankyo, as well as in projects for MorphoSys’ proprietary pipeline. Before joining VERAXA, his major focus lay on the establishment of bispecific antibody formats.